Takeaways: Health Canada’s approval of Fasenra for hypereosinophilic syndrome (HES) gives Canadian patients a much‑needed, evidence‑backed option that can cut flare‑ups and improve fatigue, potentiall...
Takeaways: Lenivia’s launch in Canada and the EU adds a three‑month, injectable biologic into Zoetis’ canine OA toolkit, which is likely to shift more chronic pain management away from dail...
Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
